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acquired immune system might have compensated for the
inﬂammatory macrophage dysfunction in the patient [14], an
invasive procedure had facilitated the inoculation of an
opportunistic pathogen deep beyond the epithelium and the
sentinel capabilities of resident macrophages. Nonetheless,
the infection was subsequently dealt with adequately by med-
ical intervention, as well as by the other intact arms of the
innate and acquired host immune response. This case adds
to our understanding of the relative clinical importance of
the role that macrophages play in invasive fungal infections.
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Abstract
This study determined the value of (1,3)-b-D-glucan (BDG), Can-
dida mannan (MN) and Candida species-speciﬁc DNA as surro-
gates for diagnosis of candidaemia. Thirty-nine patients yielding
Candida species in blood cultures were investigated for presence
of BDG, MN and Candida species-speciﬁc DNA in serum sam-
ples. The Candida spp. bloodstream isolates included C. albicans
(n = 16), C. tropicalis (n = 10), C. parapsilosis (n = 7), C. glabrata
(n = 3) and C. dubliniensis (n = 3). Positivity of the three markers
was as follows: Candida DNA for corresponding Candida species,
100%; BDG, 87%; MN, 59%. Despite varying sensitivities of these
biomarkers, they provided a useful adjunct to the diagnosis of
candidaemia.
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Timely diagnosis of candidaemia and invasive candidiasis is
crucial for improved prognosis and survival [1,2]. Due to
low blood culture positivity, the diagnostic role of non-
culture-based methods has assumed considerable signiﬁcance
[3,4]. The (1,3)-b-D-glucan (BDG) test (Fungitell), a panfungal
marker, now plays an important role in presumptive diagno-
sis of fungal infections [5,6]. Additionally, Candida mannan
(MN), a major component of the Candida cell wall that circu-
lates in the bloodstream during infection, has also been used
for the diagnosis of invasive candidiasis in European coun-
tries [7]. Although this ELISA-based test has a good speciﬁc-
ity, its low sensitivity due to rapid mannan clearance from
the circulation necessitates repeated sampling [8]. Detection
of Candida species-speciﬁc DNA in body ﬂuids is another
diagnostic alternative; however, the absence of standardized
methodology and its susceptibility to yielding false-positive/
negative results has restricted its use mainly to reference
laboratories [9]. This prospective study determined the
value of BDG, MN and Candida species-speciﬁc DNA as
surrogates for the diagnosis of candidaemia or invasive
candidiasis.
Candida spp. isolated from blood cultures (BACTEC cul-
ture system, Becton Dickinson, Sparks, MD, USA) of 39
patients were subcultured on Candida spp. differential med-
ium (Brilliance Candida; Oxoid, Basingstoke, UK). A single
representative colony was processed for identiﬁcation by the
germ tube test and Vitek2 (BioMe´rieux, Marcy l’Etoile,
France). Thirty-nine serum samples from 39 patients were
obtained within 12–24 h before starting antifungal therapy
and stored at )20C until tested. BDG levels were deter-
mined using the Fungitell kit (Associates of Cape Cod Inc.,
East Falmouth, MA, USA) and results were interpreted
according to the manufacturer’s instructions [4]. Mannan was
measured by Platelia Candida Ag Plus (BioRad, Marnes la
Coquette, France) according to the manufacturer’s instruc-
tions. A cut-off value of ‡125 pg/mL was taken as positive,
62.5 to <125 pg/mL as intermediate and <62.5 pg/mL as neg-
ative. The Mann–Whitney two-tailed test was applied to
determine signiﬁcance of differences between serum levels of
BDG and MN according to Candida species. Correlation
between BDG and MN levels was determined by the Spear-
man test. A p value of <0.05 was considered to be signiﬁ-
cant.
DNA from reference and cultured isolates of Candida spp.
was prepared as described previously [10]. DNA from serum
was extracted using the QIAamp DNA kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions. Spe-
cies-speciﬁc primer sequences and ampliﬁcation protocol
were the same as described previously [10,11]. Ampliﬁed
DNA fragments were detected by electrophoresis using 2%
agarose gels [12]. DNA from selected isolates was also sub-
jected to direct DNA sequencing of the ITS region of rDNA,
performed as described previously [13], to conﬁrm species-
speciﬁc identiﬁcation by PCR. The sequences were
compared by BLAST searches (http://www.ncbi.nlm.nih.gov/
BLAST/Blast.cgi) for species-speciﬁc identiﬁcation.
Particulars of 39 candidaemia patients, Candida species iso-
lated in blood cultures, detection of species-speciﬁc DNA,
and the levels of BDG and MN are presented in Table 1.
Sensitivity of DNA, BDG and MN detection was 100%, 87%
and 59%, respectively. Ten serum samples from healthy indi-
viduals were tested as negative controls. The mean values
for BDG and MN in control serum samples were 33.0 ± 8.7
and 40.5 ± 4.3 pg/mL, respectively. None of the serum
samples from control subjects was positive for Candida
species-speciﬁc DNA, showing 100% speciﬁcity. Twenty
serum samples from candidaemia patients were positive for
all three biomarkers, whereas DNA and BDG were addition-
ally positive in 14, and DNA and MN in three serum sam-
ples. Candida spp. identiﬁed from blood cultures included:
C. albicans (n = 16), C. tropicalis (n = 10), C. parapsilosis
(n = 7), C. glabrata (n = 3) and C. dubliniensis (n = 3)
(Table 1). All of the 39 serum samples were positive for Can-
dida DNA and corresponded with blood culture isolations,
thus showing 100% speciﬁcity. No sample was positive for
more than one Candida species by blood culture or PCR.
Positive BDG levels (‡80 pg/mL) were detected in 34 (87%)
serum samples (mean = 339 pg/mL, range 85–979 pg/mL).
Additionally, three samples yielded intermediate (60–79 pg/
mL) BDG values (i.e. 60, 72 and 77 pg/mL with correspond-
ing MN values of 40, 135 and 30 pg/mL, respectively). Posi-
tive (‡125 pg/mL) MN values were detected in 23 (59%)
serum samples while 16 (41%) samples were negative. Of
the latter 16 samples, one yielded an intermediate MN level
(65 pg/mL; Case No. 28). Two serum samples that yielded
BDG values of 43 and 52 pg/mL showed positive MN values
of 165 and 270 pg/mL, respectively. On the other hand, 14
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of 16 MN-negative serum samples showed positive (85–
752 pg/mL) BDG levels while the remaining two yielded
intermediate (77 and 60 pg/mL) BDG levels.
Mean values of BDG and Candida mannan according to
Candida species isolated from blood cultures are presented
in Table 2. The highest mean values for MN were observed
from candidaemia patients with C. tropicalis (350 ± 312 pg/
mL), followed by C. albicans (293 ± 328.0 pg/mL), C. parapsilo-
sis (166 ± 171 pg/mL), C. dubliniensis (160 ± 96 pg/mL) and
C. glabrata (151 ± 223 pg/mL). Inter-species differences in
BDG and MN levels were statistically non-signiﬁcant; how-
ever, there was a positive correlation between BDG and
MN levels (R = 0.45, p = 0.004).
The present study is noteworthy as it assesses the relative
value of BDG, MN and DNA detection in the diagnosis of
candidaemia using blood culture positivity as a reference
standard. The sensitivity of the three markers was largely
similar to other published studies [1–3]. Using a single serum
sample from each patient, sensitivity of BDG detection,
including two samples yielding BDG values in the intermedi-
TABLE 2. Range, mean and median values of Candida mannan and (1-3)-b-D-glucan levels according to Candida spp. isolated in
blood culture
Species
No of serum
samples tested
Candida mannan (pg/mL) (1-3)-b-D-glucan (pg/mL)
Range Mean ± SD Median Range Mean ± SD Median
C. albicans 16 15–845 293 ± 328 140 60–979 311 ± 260 191
C. dubliniensis 3 50–230 160 ± 96 200 175–735 498 ± 289 585
C. parapsilosis 7 20–500 166 ± 171 126 43–893 371 ± 339 275
C. tropicalis 10 30–845 350 ± 312 303 72–810 379 ± 258 320
C. glabrata 3 20–410 151 ± 223 25 106–132 121 ± 13 125
Total 39 15–845 264 ± 282 150 43–979 339 ± 268 239
TABLE 1. Comparison of Candida mannan,1-3-b-D-glucan and Candida DNA in patients yielding Candida spp. in blood culture
Case No. Age/Sex
Underlying condition/provisional
diagnosis MN BDG DNA detected for Blood culture
1 82/M Chest infection, DM 735 735 C. albicans C. albicans
2 7/F Leukaemia 35 179 C. tropicalis C. tropicalis
3 4/M Septicaemia 410 106 C. glabrata C. glabrata
4 4/F MDS 50 175 C. dubliniensis C. dubliniensis
5 3/M ALL 40 306 C. albicans C. albicans
6 3/F ALL, sepsis 465 466 C. tropicalis C. tropicalis
7 73/F Chest infection 330 810 C. tropicalis C. tropicalis
8 32/M Septic shock 525 690 C. tropicalis C. tropicalis
9 74/F COPD, DM 845 181 C. albicans C. albicans
10 65/M Septicaemia 20 275 C. parapsilosis C. parapsilosis
11 23/F Septicaemia 25 125 C. glabrata C. glabrata
12 72/M CRF 20 132 C. glabrata C. glabrata
13 52/F Septicaemia 200 735 C. dubliniensis C. dubliniensis
14 45/M Septicaemia 165 43 C. parapsilosis C. parapsilosis
15 26/F Septicaemia 845 625 C. tropicalis C. tropicalis
16 66/M DM, CRF 198 180 C. albicans C. albicans
17 56/F Septicaemia 30 195 C. albicans C. albicans
18 34 days/M Ompholocele 840 979 C. albicans C. albicans
19 65/M Septicaemia 270 52 C. parapsilosis C. parapsilosis
20 29/M BA, chest infection 30 77 C. tropicalis C. tropicalis
21 23/F Septic shock 840 188 C. albicans C. albicans
22 35/F Septicaemia 275 239 C. tropicalis C. tropicalis
23 3 months/M Epidermolysis bullosa 500 891 C. parapsilosis C. parapsilosis
24 4 months/M Septicaemia 341 589 C. albicans C. albicans
25 87/F Septicaemia 360 430 C. albicans C. albicans
26 65/M Septicaemia 130 426 C. albicans C. albicans
27 54/M Septicaemia 135 72 C. tropicalis C. tropicalis
28 47/F Chest infection 65 145 C. parapsilosis C. parapsilosis
29 40/F Burn 40 60 C. albicans C. albicans
30 11/M NHL 60 88 C. albicans C. albicans
31 40/F Corrosive ingestion 150 248 C. albicans C. albicans
32 34/F Pyelonephritis 25 184 C. albicans C. albicans
33 38/F Pulmonary infection 15 85 C. albicans C. albicans
34 54/M Septicaemia 45 109 C. albicans C. albicans
35 59/M Cancer of pancreas 126 445 C. parapsilosis C. parapsilosis
36 65/M Septicaemia 30 335 C. tropicalis C. tropicalis
37 54/M Septicaemia 835 305 C. tropicalis C. tropicalis
38 14/F Candidaemia 230 585 C. dubliniensis C. dubliniensis
39 36/M Meningitis 20 752 C. parapsilosis C. parapsilosis
DM, diabetes mellitus; MDS, myelodysplastic syndrome; COPD, chronic obstructive pulmonary disorder; CRF, chronic renal failure; NHL, non-Hodgkin’s lymphoma.
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ate range, was 92%. However, sensitivity of repeated sam-
pling for BDG estimations in patients with invasive fungal
infections was relatively higher, approaching 100% [14–16].
Although overall experience with the BDG test for diagnosis
of fungal infections is still limited, there is a consensus that
the BDG test has an excellent negative predictive value if
more than one serum sample yields negative results (<60 pg/
mL) [14,17]. However, there are also concerns regarding the
high proportion of false-positive tests, which may originate
from a variety of sources [5,16,17].
Another noteworthy ﬁnding of our study was 100%
sensitivity and 100% concordance between PCR and blood
culture results. Thus, PCR was superior to BDG or MN
detection. Other studies have reported varying sensitivities
(72–100%) and speciﬁcities (54–97%) for PCR-based diag-
nosis of candidaemia in comparison with blood culture
results [10,18–20]. Avni et al. [9] have recently reviewed
recent studies on PCR-based diagnosis of invasive candidia-
sis and concluded that direct PCR in blood samples may
offer a higher sensitivity (85%; 78–91%) than conventional
blood cultures (38%; 29–46%), as also evidenced in this
study.
Of the three markers tested, the sensitivity of MN detec-
tion in serum samples was lowest (59%). Several other stud-
ies have also reported lower sensitivity (50–60%) of this
diagnostic marker [1,18,20–22]. As serum samples in our
study were collected within 12–24 h of blood culture positiv-
ity, our data, together with previous reports, reﬂect the
inherent insensitivity of MN detection for the diagnosis of
candidaemia. The combined detection of MN and anti-MN
antibodies has, however, been shown to improve sensitivity
and speciﬁcity [1,2,18]. Nonetheless, signiﬁcant inter-species
variations in the sensitivity of the MN assay have been
reported, being highest for infections caused by C. albicans,
followed by C. glabrata and C. tropicalis [1]. Likewise, consid-
erable inter-species differences have also been reported
between Candida spp. for the BDG assay [5]. In contrast, in
the present study, MN as well as BDG levels in serum sam-
ples of patients yielding different Candida spp. in blood cul-
tures were not signiﬁcantly different (Table 2). Detection of
at least two markers is preferred for the diagnosis of candi-
daemia as it helps to minimize the possibility of false-positive
results by either test [1,22]. In this regard, our data show
that combined detection of BDG and DNA has compara-
tively higher sensitivity than detection of BDG and MN (87%
vs. 51%, respectively). A limitation of the present study is
that the speciﬁcity of the three biomarkers remains undeter-
mined because serum samples from other categories of
patients were not tested.
In conclusion, our data, based on single-sample estimation
per patient, demonstrate the utility of three tested biomar-
kers in the diagnosis of candidaemia. Further studies are
warranted to determine the utility of these markers in the
early diagnosis of invasive candidiasis in clinically suspected
patients whose blood cultures remain negative.
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